Gilead's $11B US commitment top-up Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

M T W Thu F 8 May, 2025

FDA upheaval and tariff wars are reshaping biotech’s landscape. Join Editor-in-Chief John Carroll and industry leaders as they decode Endpoints 100 survey data revealing how executives are navigating these extraordinary challenges. Where do they see opportunity, if any? Find out — sign up today.

presented by In one of the riski­est in­dus­tries — Biotech — a sure­fire way to neu­tral­ize some of that risk emerges

news Lantheus culls late-stage Lilly-partnered prostate cancer radioligand Teva plans staff cuts as it commits to accelerating growth Gilead reveals plans to put another $11B into US manufacturing

Research Associate I/II - Gene Therapy MeiraGTx New York, NY, USA Senior Drug Development Clinician Weatherden London, UK Head of Clinical Operations ModeX Therapeutics Inc. Weston, MA 02493, USA Senior Scientist, Analytical Development Precision BioSciences Durham, NC Recruit talent with Endpoints Careers Contact Meg Estacio: mestacio@endpointsnews.com

Exploring Japan as a key market for your drug? Get the roadmap — join senior Japanese leaders to hear firsthand on the regulatory and pricing dynamics behind one of the world’s top pharma markets. Sign up now.

endpoints pharma From deal to disaster: Drugmakers face a changed Washington as Trump embraces ‘most favored nation’ prices PhRMA says tariffs are 'not the answer' as industry trade probe closes for comments FDA's ODAC will review drugs for four different cancers at meeting in May FDA will convene vaccine advisors to discuss Covid strain updates Compounders just lost their case to put obesity drug tirzepatide back in shortage

May 12 1:30pm ET How to incorporate pragmatic design elements into your clinical studies sponsored by Flatiron May 29 10:30am ET Optimizing the clinical research workforce - An industry analysis by Parexel sponsored by Parexel Jun 03 11:00am ET Building robust health system partnerships for life sciences sponsored by Advisory Board

in case you missed it 1. Biotech stocks plunge and industry figures left to wonder after Prasad's FDA appointment •  What Vinay Prasad means for CBER, vaccines, drug approvals and more 2. CRISPR Therapeutics' gene editing therapy reduces bad cholesterol and triglycerides by as much as 80%